TSLPR-CART

TSLPR-CART is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting the thymic stromal lymphopoietin receptor (TSLPR), which is encoded by the CRLF2 gene. Developed by the National Cancer Institute (NCI), this therapy is specifically designed for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) characterized by CRLF2 rearrangements (CRLF2-R), which lead to the overexpression of TSLPR on the surface of leukemic blasts. The treatment process involves collecting a patient's T cells via leukapheresis, genetically engineering them to express a CAR specific for TSLPR, and re-infusing them into the patient following lymphodepleting chemotherapy. Once infused, the CAR-T cells recognize and bind to TSLPR-expressing cancer cells, triggering targeted cell lysis. It is currently being evaluated in Phase I clinical trials for safety and efficacy in adult patients with recurrent or refractory CRLF2-R/TSLPR-overexpressing B-ALL.